This is still only about 158 million market cap, 3
Post# of 72430
AVXLD, 256 million market cap, 1 drug in one Phase 2A trial in AUSTRALIA not U.S. (and in the extremely risky Alzheimers area). [Disclaimer: I own AVXLD and have big profits -- not badmouthing the stock.]
GALE, 272 million market cap, terrible management, all kinds of problems with their drug and trials.
SYN 206 million market cap, terrible management did a secondary offering at 2/3 of the then current stock price. Possibly good drugs, I have owned it and probably will again.
AXON, 1.2 Billion (yes, Billion with a
![B) B)](smileys/cool.gif)
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)